VAD or VMBCP in severe multiple myeloma
| Autor: | A. de Gramont, Mathieu Monconduit, Marc Wetterwald, Jean-François Ménard, Isabelle Azais, J. Ph. Laporte, Liana Euller-Ziegler, JL Michaux, Chantal Doyen, Bernard Grosbois, X. Le Loet, J. P. Pollet, J.F. Bernard, B. Duclos, A. M. Peny |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Response rate (survey)
medicine.medical_specialty Chemotherapy business.industry medicine.medical_treatment Significant difference Hematology medicine.disease Surgery law.invention Clinical trial Randomized controlled trial law Internal medicine Immunopathology parasitic diseases medicine cardiovascular diseases biological phenomena cell phenomena and immunity Stage (cooking) business Multiple myeloma |
| Zdroj: | British Journal of Haematology. 80:199-204 |
| ISSN: | 0007-1048 |
| DOI: | 10.1111/j.1365-2141.1992.tb08901.x |
| Popis: | A randomized trial has been performed in which 91 patients with stage III myeloma and additional severe criteria were randomly allocated to either VAD or VMBCP. No significant difference was noted between these two groups using the following criteria: response rate (VMBCP: 54%; VAD: 39%), impact on symptoms, median survival (VMBCP: 14 months, VAD: 17 months). However, toxic effects and refusal to pursue treatment were more frequent with VAD than with VMBCP (12 v 6). Therefore, in this trial, VMBCP appears to be more useful than VAD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text